Insulin producer Eli Lilly and Company announced on Mar. 1 that the company will cap patient out-of-pocket costs at $35 or less per month in an effort to increase access and affordability. Lilly will cut the costs of Humalog, the company’s most commonly prescribed insulin, and another insulin called Humulin by 70% beginning in the fourth quarter which starts in October.Insulin users often go through several vials of insulin per month. One vial of Humalog is listed with a cost of $275, which Lilly plans to reduce to $66. Lilly also announced that it will reduce the cost of its non-branded insulin, Insulin Lispro Injection, to $25 a vial beginning May 1, 2023. This will make the generic insulin the lowest “list-priced mealtime insulin available.”